Brief: Spero Therapeutics Inc Says Existing Cash And Cash Equivalents, Expected To Be Sufficient To Fund Operations And Capex Beyond 2024
09/01/2023 13:14
Jan 9 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS INC - EXISTING CASH AND CASH
EQUIVALENTS,
EXPECTED TO BE SUFFICIENT TO FUND OPERATIONS AND CAPEX BEYOND
2024
Source text for Eikon: ID:
Further company coverage: SPRO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)